Schizophrenia Clinical Trial
Official title:
Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia
This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
Schizophrenia is a chronic and severe brain disorder that can significantly impact quality
of life. It is characterized by delusions, paranoia, and disordered thinking. The cause of
schizophrenia has not yet been determined. However, there are many treatments, including
drug therapy and cognitive behavioral therapy, that may help to alleviate symptoms of the
condition. Nicotinic receptors are involved in a number of biological processes; they are
numerous throughout the central and peripheral nervous systems and are diverse in structure
and expression. Genetic and neurobiological research has identified decreased expression of
the a7 nicotinic receptor as an element in schizophrenia that is related to poor
psychosocial outcome. Data indicate that drug therapy may reduce this deficit in receptor
expression. Nicotine has been found to stimulate the a7 nicotinic receptor; however, the
physiological dependence associated with nicotine makes it an undesirable option.
Dimethoxbenzylidene anabaseine (DMXB-A) can stimulate the a7 nicotinic receptor; its
advantages include easy oral administration and the lack of dependence-causing effects. This
study will determine whether DMXB-A can safely and effectively stimulate the a7 nicotinic
receptor in schizophrenia patients and reduce their neurobiological symptoms.
This study will last 6 weeks. Participants will have study visits each week for the duration
of the study. During each visit, participants will be randomly assigned to receive either
DMXB-A or placebo. An electrocardiogram (EKG) will measure the heart function of
participants and participants' blood pressure will be measured. After the first dose of
either DMXB-A or placebo, participants will receive a second dose 2 hours later. An evoked
potential test, which measures the brain's response to stimuli, will be performed after both
doses. Neuropsychological tests, such as verbal reasoning and visual retention, will be
performed following the second dose of either DMXB-A or placebo.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |